Please login to the form below

Not currently logged in
Email:
Password:

Prosensa

This page shows the latest Prosensa news and features for those working in and with pharma, biotech and healthcare.

BioMarin gives up on muscular dystrophy drug

BioMarin gives up on muscular dystrophy drug

The announcement marks the culmination of an expensive gamble for BioMarin, which paid $840m to buy drisapersen's developer Prosensa at the end of 2014.

Latest news

More from news
Approximately 4 fully matching, plus 15 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
SEVEN STONES

Seven Stones is a creative, independent healthcare communications agency of movers and thinkers. We've been doing health differently since 1991....

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...

Infographics